Clinical Trials Browser

Phase 2 × Endoscopic Mucosal Resection × 90 days × Clear all

NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Phase 2 Active not recruiting

17 enrolled 14 charts

Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8